Mikael Saulay

Allschwil, BL, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

Journal: PloS one

Published: February 25, 2025

Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.

Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.

Journal: The Journal of antimicrobial chemotherapy

Published: November 05, 2024

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

Journal: JNCI cancer spectrum

Published: November 27, 2023

Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.

Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.

Journal: The New England journal of medicine

Published: September 27, 2023

A post hoc analysis of two Phase III trials showing the efficacy and tolerability of ceftobiprole in East Asian patients.

A post hoc analysis of two Phase III trials showing the efficacy and tolerability of ceftobiprole in East Asian patients.

Journal: Future microbiology

Published: June 22, 2021

Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies.

Efficacy and safety of ceftobiprole in patients aged 65 years or older: a post hoc analysis of three Phase III studies.

Journal: Future microbiology

Published: May 07, 2021

A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.

A Phase 3, Randomized, Investigator-blinded Trial Comparing Ceftobiprole With a Standard-of-care Cephalosporin, With or Without Vancomycin, for the Treatment of Pneumonia in Pediatric Patients.

Journal: The Pediatric infectious disease journal

Published: January 22, 2021

Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).

Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET).

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: March 19, 2020

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial.

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial.

Journal: Future microbiology

Published: January 11, 2020

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials.

Journal: BMC infectious diseases

Published: September 04, 2018

Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.

Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.

Journal: The Journal of antimicrobial chemotherapy

Published: July 16, 2018

Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.

Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.

Journal: Mycoses

Published: June 08, 2018

Showing 1-12 of 13

Last Updated: 09/26/2026